Cor Vasa 2021, 63(6):737-740 | DOI: 10.33678/cor.2021.137

(Ferric carboxymaltose - a promising molecule in the treatment of iron deficiency in patients with heart failure)

Mária Bakošová^{a, b}, Jan Krejčí^{a, b}, Lenka Špinarová^{a, b}

^a I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny v Brně, Brno

^b Lékařská fakulta Masarykovy univerzity, Brno

The authors summarize the new findings on iron deficiency in patients with heart failure recently reflected in the new guidelines for the management of the heart failure. In addition to recapitulating previous evidence, they discuss the results of the AFFIRM-HF trial, which extended the indication of ferric carboxymaltose to patients after acute decompensation of heart failure. It has been shown that after intravenous iron supplementation there is an improvement in symptoms, performance and a reduction in hospital admissions for heart failure decompensation. The text is supplemented by a case report describing the case of a 60-year-old female patient with heart failure of ischemic etiology who was found to be iron deficient when her condition worsened, and there was a significant improvement in symptomatology after intravenous administration of ferric carboxymaltose. The case report is followed by a review of our own experience in monitoring and treating iron deficiency in patients with heart failure.

Keywords: Anemia, Ferric carboxymaltose, Ferritin, Heart failure, Iron deficiency, Transferrin saturation

Received: December 4, 2021; Accepted: December 4, 2021; Published: December 13, 2021  Show citation